Industry Reports Services Press Release
  •   Blogs
  • Contact us About us

    European In Vitro Diagnostic Market size is estimated to surpass USD 27.6 billion by 2027, according to a latest forecast report by Graphical Research.

    In vitro diagnostics (IVD) is an umbrella term involving tests used to diagnose a several disorders using samples such as blood or tissues collected from the human body. In vitro diagnostics can help to diagnose and prevent diseases by detecting them early and monitoring a patient’s overall health. Precision medicine approach also uses in vitro diagnostics to identify patients who are likely to benefit from specific treatments or therapies. The in vitro diagnostics also includes next generation sequencing tests, that are used to scan a person’s DNA to detect genomic variations. Many people today are thriving years after being diagnosed with some of the world's deadliest diseases, such as cancer and heart disease, as well as infectious diseases such as hepatitis and HIV. Much of that progress has been made possible by IVD innovation, which improves doctors' ability to act on the right information at the right time. Furthermore, growing adoption of personalized medicine, technological advancements in IVD and increasing incidence of infectious and chronic diseases further propel the market growth.

    The reagent & kits segment in the Europe IVD market was USD 11 billion revenue in 2020 attributed to increasing constant testing for infectious diseases during the COVID-19 pandemic. In addition, increased research and development activities in this region to launch diagnostic tests for various chronic diseases, as well as surging demand for cost effective laboratory diagnostic kits in resource-limited countries, will positively promote segment growth. Furthermore, increasing product launches and growing awareness about advanced technologies among individuals will spur the market demand. For instance, in January 2020, Sysmex announced the launch of ipsogen JAK2 DX Reagent, a gene testing kit for blood cancer. Such new product launch will enhance company product portfolio and market progression.

    The hematology segment accounted around 16% market share in 2020 credited to the increasing prevalence of blood disorders coupled with rising popularity of automated hematology analyzers. For instance, according to the data published by Health Economics Research Centre of the University of Oxford, in 2016, blood disorders affect around 80 million people in the Europe. Also, report stated that, blood disorders cost €23 billion every year in Europe. Furthermore, POC hematology tests are user-friendly since they minimize the requirement for user involvement while also allowing for remote testing. Increasing adoption of these tests along with new product launch is expected to propel the market revenue. For instance, in March 2021, Sysmex released its XR-Series Automated Hematology Analyzer. It is company’s next generation flagship model in the hematology segment. This automated analyzer will offer improved efficiency by using digital waveform processing to increase the differential WBC count.

    Browse detailed statistical insights from the report, “Europe In Vitro Diagnostics (IVD) Market Forecast 2027 By Application (Oncology, Infectious Diseases, Diabetes, Cardiology, Nephrology, Autoimmune Diseases, Drug Testing/ Pharmacogenomics), By Product Type (Reagents & Kits, Instruments), By Test Type (Clinical Chemistry, Immunoassay/ Immunochemistry, Molecular Diagnostics, Hematology, Urinalysis), By End-Use (Hospitals, Diagnostic Laboratories, Academic & Research Institutes), Research Report, Country Outlook (Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Poland, Denmark, Sweden, Finland, Norway), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @


    The European in vitro diagnostic (IVD) market form nephrology segment was valued at USD 893 million revenue in 2020 due to rise in prevalence of chronic kidney disease in Europe.  According to data published by Kidney Care UK, it is estimated that approximately 3 million people have chronic kidney disease (CKD) and every day around 20 people suffer kidney failure in the UK. Furthermore, increasing advancement in in vitro diagnostic products coupled with growing adoption in this region will spur the market size.

    The hospital segment held over 39% European in vitro diagnostic market share and dominated around USD 6.5 billion in 2020. The factor such as availability of well-equipped diagnostic labs as well as skilled healthcare professionals in hospital facilities are responsible for the industry growth. Furthermore, when compared to independent diagnostic laboratories, the turnaround time for any diagnostic test in a hospital is shorter. In hospitals, all labs from microbiology to molecular diagnostics are housed under one roof and in the case of emergency, patients can immediately consult with a doctor.

    The Germany in vitro diagnostic market is projected to witness 5.2% CAGR during the analysis period owing to the presence of key players that are constantly focusing on development of new IVD product based on nucleic acid amplification for the detection of infectious diseases. Furthermore, due to the COVID-19 pandemic, there is an increase in demand for next-generation sequencing, serology-based rapid-test products, polymerase chain reaction in the Germany, which is anticipated to drive the market expansion. Furthermore, these factors have enabled market participants to improve and strengthen their current manufacturing and distribution capabilities, as well as focus on product commercialization.

    The European in vitro diagnostic market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2016 to 2027, for the following segments:

    Europe Market, By Product Type

    • Reagents & kits
    • Instruments

    Europe Market, By Test Type

    • Clinical chemistry 
    • Immunoassay/Immunochemistry 
    • Molecular diagnostics
    • Hematology 
    • Urinalysis 
    • Others

    Europe Market, By Application

    • Oncology 
    • Infectious diseases
    • Diabetes 
    • Cardiology 
    • Nephrology 
    • Autoimmune diseases 
    • Drug testing/pharmacogenomics 
    • Others

    Europe Market, By End-use

    • Hospitals
    • Diagnostic laboratories
    • Academic & research institutes
    • Others

    The above information has been provided for the following countries:

    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Netherlands
      • Switzerland
      • Poland
      • Denmark
      • Sweden
      • Finland
      • Norway
      • Others